FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.
Previous Post
Patient Satisfaction Higher With Certain Breast Reconstruction Techniques
Next Post
Study of IPF, Cardiovascular Disease Suggests Complex Interplay
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago